Congenital Adrenal Hyperplasia Market Size was USD 20 million in 2023 and is projected to grow at a rapid CAGR by 2034

The Congenital Adrenal Hyperplasia market size was valued approximately USD 20 million in 2023 and  is anticipated to grow with a significant CAGR during the study period (2020-2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Congenital Adrenal Hyperplasia landscape.

In 2023, the United States dominated the Congenital Adrenal Hyperplasia market within the 7MM, representing nearly 60% of the total market share. During the same year, steroid-based therapies for congenital adrenal hyperplasia brought in around USD 7 million in revenue across the EU4 nations and the United Kingdom.

Within the 7MM, the United States reported the highest number of prevalent congenital adrenal hyperplasia cases in 2023, totaling roughly 32,000, and this figure is anticipated to grow throughout the forecast period. In the US, the condition was more common among males, with about 19,000 affected compared to approximately 13,000 females in 2023. Across the 7MM, adults aged over 18 represented the largest affected population segment, recording nearly 36,000 cases in 2020, which is expected to reach around 50,000 by 2034.

DelveInsight’s report, “Congenital Adrenal Hyperplasia Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Congenital Adrenal Hyperplasia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. 

Additionally, it examines Congenital Adrenal Hyperplasia market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Congenital Adrenal Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congenital Adrenal Hyperplasia Market Forecast

Some of the key facts of the Congenital Adrenal Hyperplasia Market Report: 

• Key Congenital Adrenal Hyperplasia Companies: Crinetics Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences, Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics Pharmaceuticals Inc., Spruce Biosciences, Neurocrine Biosciences, Millendo Therapeutics, Inc, Adrenas Therapeutics Inc, Diurnal Limited, Novartis, and others
• Key Congenital Adrenal Hyperplasia Therapies: Atumelnant(CRN04894), Lu AG13909, EFMODY (Hydrocortisone Modified-release Hard Capsules), Tildacerfont, NBI-74788, BBP-631, CRN04894, SPR001, Crinecerfont, ATR-101, AAV BBP-631, Chronocort, Osilodrostat, and others
• The Congenital Adrenal Hyperplasia epidemiology based on gender analyzed that no gender related difference was observed in case of Congenital Adrenal Hyperplasia
• The Congenital Adrenal Hyperplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congenital Adrenal Hyperplasia pipeline products will significantly revolutionize the Congenital Adrenal Hyperplasia market dynamics.

Congenital Adrenal Hyperplasia Overview

Congenital Adrenal Hyperplasia (CAH) is a group of inherited genetic disorders that affect the adrenal glands small glands located above the kidneys that produce hormones like cortisol, aldosterone, and androgens. In CAH, a deficiency of certain enzymes, most commonly 21-hydroxylase, disrupts normal hormone production.
As a result, the body may produce insufficient cortisol and aldosterone while generating excess androgens (male hormones), leading to symptoms such as abnormal genital development, early puberty, fertility issues, salt-wasting crises, and growth abnormalities. CAH is typically diagnosed in infancy or childhood and requires lifelong hormone replacement therapy and careful medical management.

Get a Free sample for the Congenital Adrenal Hyperplasia Market Report:

https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market

Key Trends in Congenital Adrenal Hyperplasia Therapeutics Market:

• Shift Toward Novel and Targeted Therapies Beyond Steroids: Growing focus on steroid-sparing therapies and precision medicines such as CRF1 receptor antagonists and gene-based approaches is transforming long-term disease management and reducing steroid-related side effects.
• Advancements in Gene and Cell-Based Therapies: Increasing R&D in gene editing and gene replacement strategies offers the potential for disease-modifying or curative treatment options, significantly influencing future market growth.
• Increase in Clinical Trials and Strong Pipeline Activity: A robust pipeline featuring candidates like tildacerfont, crinecerfont, and ATR-101 is driving competition and innovation within the CAH therapeutic landscape.
• Improved Diagnostic and Newborn Screening Practices: Enhanced screening programs and earlier identification of CAH are expanding the diagnosed patient pool and boosting demand for effective long-term therapies
• Rising Patient Advocacy and Awareness Initiatives: Growing support from patient organizations and improved education are pushing for better treatment access, reimbursement, and quality of life outcomes.

Congenital Adrenal Hyperplasia Epidemiology

The Congenital Adrenal Hyperplasia epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Congenital Adrenal Hyperplasia Epidemiology Segmentation:

The Congenital Adrenal Hyperplasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of CAH in the 7MM
• Total Diagnosed Prevalent Cases of CAH in the 7MM
• Type-specific Diagnosed Prevalent Cases of CAH in the 7MM
• Gender-specific Diagnosed Prevalent Cases of CAH in the 7MM
• Treated Cases CAH in the 7MM

Download the report to understand which factors are driving Congenital Adrenal Hyperplasia epidemiology trends @ Congenital Adrenal Hyperplasia Epidemiology Forecast

Recent Development In The Congenital Adrenal Hyperplasia Treatment Landscape: 

• In August 2025, Crinetics Pharmaceuticals (Nasdaq: CRNX) reported that the FDA has awarded Orphan Drug Designation to atumelnant, a novel, first-in-class oral ACTH receptor antagonist taken once daily, for the treatment of classic congenital adrenal hyperplasia (CAH).
• In June 2025, Lundbeck reported receiving ODD in the US and EU for Lu AG13909 in CAH, highlights its potential in CAH and reinforces regulatory support for advancing innovative therapies in rare endocrine disorders.
• In May 2025, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has released new findings from its Phase 3 CAHtalyst™ Adult and Pediatric trials evaluating CRENESSITY™ (crinecerfont). The results revealed that a significant number of pediatric patients with classic congenital adrenal hyperplasia (CAH) reached glucocorticoid doses within the physiological range and achieved normal androstenedione levels. Furthermore, adult male patients showed improvements in certain reproductive hormone levels. Both groups adults and children experienced notable reductions in glucocorticoid dosing. These findings were shared at the 2025 Annual Meeting of the American Association of Clinical Endocrinology in Orlando.

Congenital Adrenal Hyperplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congenital Adrenal Hyperplasia market or expected to get launched during the study period. The analysis covers Congenital Adrenal Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congenital Adrenal Hyperplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Congenital Adrenal Hyperplasia Therapies and Key Companies

• Atumelnant(CRN04894) : Crinetics Pharmaceuticals
• Lu AG13909: H. Lundbeck A/S
• EFMODY (Hydrocortisone Modified-release Hard Capsules): Neurocrine Biosciences
• Tebipenem Pivoxil Hydrobromide (SPR994): Spero Therapeutics
• Cefepime/zidebactam (WCK-5222): Wockhardt
• Cefepime/taniborbactam: Venatorx Pharmaceuticals
• Tildacerfont: Spruce Biosciences
• NBI-74788 Neurocrine Bioscience
• BBP-631: BridgeBio Pharma
• CRN04894: Crinetics Pharmaceuticals Inc.
• SPR001: Spruce Biosciences
• Crinecerfont: Neurocrine Biosciences
• ATR-101: Millendo Therapeutics, Inc.
• AAV BBP-631: Adrenas Therapeutics Inc
• Chronocort: Diurnal Limited
• Osilodrostat: Novartis

Discover more about therapies set to grab major Congenital Adrenal Hyperplasia market share @ Congenital Adrenal Hyperplasia Treatment Market

Congenital Adrenal Hyperplasia Market Drivers

• Rising prevalence of CAH globally, increasing the need for effective treatments.
• Advancements in newborn screening programs, enabling early diagnosis and intervention.
• Development of novel therapies, including enzyme replacement and gene therapy approaches.
• Growing awareness among healthcare professionals and caregivers about CAH management.
• Supportive regulatory environment and orphan drug incentives promoting R&D for rare diseases.

Congenital Adrenal Hyperplasia Market Barriers

• High treatment costs and limited access in certain regions, restricting patient reach.
• Complexity of lifelong hormone replacement therapy, requiring careful monitoring and dose adjustments.
• Potential side effects of long-term steroid therapy, including growth suppression and metabolic issues.
• Small patient population, limiting large-scale clinical trials and market expansion.
• Variability in disease severity and presentation, complicating standardized treatment approaches.

Scope of the Congenital Adrenal Hyperplasia Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Congenital Adrenal Hyperplasia Companies: Crinetics Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences, Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics Pharmaceuticals Inc., Millendo Therapeutics, Inc, Adrenas Therapeutics Inc, Diurnal Limited, Novartis, and others
• Key Congenital Adrenal Hyperplasia Therapies: Atumelnant(CRN04894), Lu AG13909, EFMODY (Hydrocortisone Modified-release Hard Capsules), Tildacerfont, NBI-74788, BBP-631, CRN04894, SPR001, Crinecerfont, ATR-101, AAV BBP-631, Chronocort, Osilodrostat, and others
• Congenital Adrenal Hyperplasia Therapeutic Assessment: Congenital Adrenal Hyperplasia current marketed and Congenital Adrenal Hyperplasia emerging therapies
• Congenital Adrenal Hyperplasia Market Dynamics: Congenital Adrenal Hyperplasia market drivers and Congenital Adrenal Hyperplasia market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Congenital Adrenal Hyperplasia Unmet Needs, KOL’s views, Analyst’s views, Congenital Adrenal Hyperplasia Market Access and Reimbursement

To know more about Congenital Adrenal Hyperplasia companies working in the treatment market, visit @ Congenital Adrenal Hyperplasia Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.